Objective: To investigate the efficacy of ibandronate sodium and zoledronate sodium in the treatment of senile osteoporosis and their impact on quality of life, and to analyze the cost-effectiveness.
Methods: A retrospective study was conducted on 215 patients with senile osteoporosis, who were admitted to our hospital from January 2017 to June 2019. Among them, 115 cases treated with ibandronate sodium were set to group A and 100 cases treated with zoledronate sodium were set to group B. The clinical efficacy, bone mineral density (BMD) before and after treatment, bone metabolic markers (alkaline phosphatase (ALP), blood phosphorus (P), blood calcium ion (Ca)), quality of life, adverse reactions, cost-effectiveness indicators (length of hospitalization, cost) and complications were compared between the two groups.
Results: Total therapeutic response rate in group A was 96.52% (111/115), which was not statistically different from that of 93.00% (93/100) in group B (P=0.242). After treatment, the BMD, ALP, BGP and Ca levels of the lumbar spine L1-L4, left femoral neck and right femoral neck, as well as quality of life scores in the two groups increased (P < 0.05), while serum ALP levels decreased (P < 0.05), however, there was no statistically significant difference between the two groups (P > 0.05). The incidence of adverse reactions in group A was 3.48% (4/115), which showed no statistical significance with that of 5.00% (5/100) in group B (P=0.830). The length of hospitalization, annual treatment expense, medical insurance expense and out-of-pocket payments in group A were all lower than those in group B (P < 0.05).
Conclusion: In the treatment of senile osteoporosis, the efficacy and adverse reactions of ibandronate sodium and zoledronate sodium are similar, both of them can effectively improve the quality of life. However, the cost-effectiveness of ibandronate sodium is better than that of zoledronate sodium.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014411 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Novel Approaches to Monitor Pharmacokinetics and Metabolism of Gemcitabine-Ibandronate Conjugate in Mice and Dogs.
Molecules
January 2025
MBC Pharma Inc., Aurora, CO 80045, USA.
Background: The use of the bone-seeking properties of bisphosphonates (BPs) to target the delivery of therapeutic drugs is a promising approach for the treatment of bone metastases. Currently, the most advanced example of this approach is a gemcitabine-ibandronate conjugate (GEM-IB), where the bone-targeting BP ibandronate (IB) is covalently linked to the antineoplastic agent gemcitabine (GEM) via a spacer phosphate group. In the present study, we describe the development of a new analytical platform to evaluate the metabolism and pharmacokinetics of GEM-IB in mice and dogs and the results of proof-of-concept studies assessing the pharmacokinetics of GEM-IB in dogs and mice.
View Article and Find Full Text PDFEvaluation and analysis of efficacy in bisphosphonate treatment of chronic nonbacterial osteomyelitis.
Hua Xi Kou Qiang Yi Xue Za Zhi
February 2025
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Dept. of Pharmacy, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Objectives: This study aimed to analyze the influence of drug factors on the efficacy of bisphosphonate for chronic nonbacterial osteomyelitis to provide a reference for clinical treatment and promote clinical rational drug use by evaluation of effectiveness and safety of bisphosphonate treatment of chronic nonbacterial osteomyelitis.
Methods: Literature on the treatment of chronic nonbacterial osteomyelitis by using bisphosphonate was collected and analyzed from PubMed, Medline, Embase, Cochrane, ISI Web of Knowledge, CNKI, VIP, and Wanfang databases.
Results: A total of 489 cases were collected, with an average complete response rate of clinical presentation, laboratory tests and imaging findings of 80.
Bone-Marrow-Targeted Nanocomposite Abrogates C-Myb-Survivin Cross Talk in MLL-AF9-Rearranged Acute Myeloid Leukemia in and Patient-Derived Xenograft Models.
ACS Appl Mater Interfaces
January 2025
Epigenetics Research Laboratory, Institute of Nano Science and Technology, Knowledge City, Sector 81, Mohali, Punjab 140306, India.
The heterogeneous form of malignancy in the myeloid lineage of normal hematopoietic stem cells (HSCs) is characterized as acute myeloid leukemia (AML). The t(9;11) reciprocal translocation (p22;q23) generates MLL-AF9 oncogene, which results in myeloid-based monoblastic AML with frequent relapse and poor survival. MLL-AF9 binds with the C-Myb promoter and regulates AML onset, maintenance, and survival.
View Article and Find Full Text PDFIn Vitro Effects of Some Chemotherapeutics on Human Erythrocyte Glucose-6-Phosphate Dehydrogenase Enzyme.
ACS Omega
December 2024
Faculty of Veterinary Science, Department of Biochemistry, Bingöl University, Bingöl 12000, Turkiye.
In this study; the in vitro effects of some drugs used in chemotherapy on the glucose-6-phosphate dehydrogenase enzyme (G6PD; E.C. 1.
View Article and Find Full Text PDFTibial Insufficiency Fracture with Characteristics of an Atypical Fracture: A Rare Case and Literature Review.
Medicina (Kaunas)
November 2024
Department of Orthopedic Surgery, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-Ro, Yeongdeungpo-Gu, Seoul 07345, Republic of Korea.
Article Synopsis
- - Osteoporosis is increasingly common due to an aging population, leading to more patients using bisphosphonates for treatment, which can prevent fractures but also cause atypical insufficiency fractures over time.
- - A case study of a 76-year-old woman on long-term bisphosphonate therapy revealed an atypical insufficiency fracture in her tibia, which was confirmed through imaging and examination.
- - After conservative treatment failed, the patient underwent surgery and successfully healed, highlighting the need for clinicians to investigate unexplained pain in weight-bearing bones among individuals on prolonged bisphosphonate therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!